Company profile for Eisai Inc

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

At Eisai Inc., human health care (hhc) is our goal. We give our first thought to patients and their families, and help to increase the benefits health care provides. As the U.S. pharmaceutical subsidiary of Tokyo-based Eisai Co., Ltd., the company has a passionate commitment to patient care that is the driving force behind our efforts to discover and develop innovative therapies to help address unmet medical needs. Eisai is a ...
At Eisai Inc., human health care (hhc) is our goal. We give our first thought to patients and their families, and help to increase the benefits health care provides. As the U.S. pharmaceutical subsidiary of Tokyo-based Eisai Co., Ltd., the company has a passionate commitment to patient care that is the driving force behind our efforts to discover and develop innovative therapies to help address unmet medical needs. Eisai is a fully integrated pharmaceutical business that operates in two global business groups: oncology and neurology (dementia-related diseases and neurodegenerative diseases).

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
200 Metro Blvd, Nutley, NJ 07110
Telephone
Telephone
+1 2016921100
youtube
YouTube

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

IMCAS World Congress

IMCAS World Congress

Not Confirmed

envelop Contact Supplier

IMCAS World Congress

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.prnewswire.com/news-releases/eisai-submits-marketing-authorisation-variation-to-ema-for-intravenous-maintenance-dosing-every-four-weeks-with-leqembi-lecanemab-302670394.html

PR NEWSWIRE
26 Jan 2026

https://www.eisai.com/news/2026/news202605.html

GLOBENEWSWIRE
25 Jan 2026

https://www.fiercebiotech.com/biotech/chutes-ladders-bms-snags-top-neuro-researcher-eisai

FIERCE BIOTECH
23 Jan 2026

https://www.pharmiweb.com/press-release/2026-01-12/nuvation-bio-and-eisai-enter-into-exclusive-licensing-agreement-for-taletrectinib-in-europe-and-addi

PHARMIWEB
12 Jan 2026

https://www.prnewswire.com/news-releases/bla-for-subcutaneous-formulation-of-leqembi-accepted-in-china-302653787.html

PR NEWSWIRE
06 Jan 2026

https://www.globenewswire.com/news-release/2026/01/06/3213279/0/en/Biologics-License-Application-for-Subcutaneous-Formulation-of-LEQEMBI-lecanemab-for-the-Treatment-of-Early-Alzheimer-s-Disease-Accepted-in-China.html

GLOBENEWSWIRE
05 Jan 2026

Inspections and registrations

Upload your audits for free, ask us

ABOUT THIS PAGE

Contact Eisai Inc and get a quotation

Eisai Inc is a supplier offers 3 products (APIs, Excipients or Intermediates).

Find a price of MOH040 bulk with DMF offered by Eisai Inc

Find a price of INTERLEUKIN-2 DIPHTHERIA TOXIN FUSION PROTEIN (DAB 389 IL-2) bulk offered by Eisai Inc

Find a price of Eperisone Hydrochloride bulk offered by Eisai Inc

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty